For patients with a severe traumatic brain injury, the most important number in the ICU is the one inside their skull. Intracranial pressure, or ICP, dictates whether a clinician escalates sedation, drains cerebrospinal fluid, or rushes the patient back to the OR. Today, getting that number reliably means drilling a small hole in the skull and threading in a probe. CranioSense, a clinical-stage neurotechnology company in Waltham, Massachusetts, is trying to replace that bolt with a sensor that sits on the outside of the head.
The company's wedge is a device it calls IPASS, which it describes as a noninvasive system for rapid and continuous ICP readings intended to give clinicians "objective, actionable information to manage the patient in the interim, helping to avoid secondary brain damage" [MTEC, 2026]. In December, CranioSense said it had been awarded approximately $5.5 million in non-dilutive federal grant funding through the NIH Blueprint MedTech Program and a U.S. Department of Defense channel to advance device development and clinical validation ahead of a planned market launch [Pulse2, 2025]; [MedTech Innovator, 2025]. For a small medtech company, that is a meaningful runway extension that does not touch the cap table.
The standard of care today
For patients with severe TBI, hydrocephalus, or suspected intracranial hypertension, the reference standard for measuring ICP is an invasive monitor: either an external ventricular drain (EVD) placed into a ventricle of the brain, or an intraparenchymal "bolt" sensor inserted through the skull. Both are accurate, both are the basis of Brain Trauma Foundation guideline-directed care, and both carry real downsides: infection risk, hemorrhage risk, the need for a neurosurgeon, and the practical reality that they are typically only available at Level 1 trauma centers. Patients in community hospitals, in transport, or in field settings often go without ICP data entirely, and clinicians manage based on imaging and exam findings that lag the underlying physiology. That gap, between the patients who could benefit from continuous ICP information and the patients who actually get it, is the market CranioSense is aiming at.
The bet
CranioSense was formed by Vivonics, a Waltham-based device development firm, specifically to attract private investment and shepherd IPASS through FDA clearance and to market [MTEC, 2026]. That origin story matters. It means IPASS did not begin life as a software demo looking for a clinical application; it began as a hardware program inside a contract engineering shop that has worked on Department of Defense medical technology, then was spun out when the technology looked credible enough to commercialize.
The commercial pitch, if validation holds, is straightforward. A noninvasive ICP readout could move ICP monitoring upstream from the neuro-ICU into the emergency department, into ground and air transport, into community hospitals, and potentially into outpatient follow-up for conditions like idiopathic intracranial hypertension and shunted hydrocephalus. The company describes its mission as "simplifying the diagnostic process for intracranial hypertension" [Crunchbase, 2025], which is a narrower beachhead than the full TBI market and one where patients today often cycle through repeat lumbar punctures and imaging.
Why the funding mix is interesting
CranioSense's disclosed capital stack is unusual for a seed-stage hardware company. Alongside a small $20,000 Techstars seed check [Tracxn, 2025], the company has now stacked roughly $5.5 million in federal grants [Pulse2, 2025]. Angel groups including Illinois Venture Angels, She's Independent, Heinz Ventures, and Hillside Ventures are also on the cap table.
Federal grants (NIH Blueprint MedTech + DoD) | 5.5 | $M
Techstars seed | 0.02 | $M
Non-dilutive grant funding from the NIH Blueprint MedTech Program is competitive and comes with milestone-based oversight, which is itself a soft signal that reviewers found the underlying science worth funding to a clinical validation stage. It also means CranioSense can run the expensive part of a medtech program, the pivotal-style human studies needed to support an FDA submission, without compressing a Series A around a binary readout.
The team
CranioSense was founded in 2015 by Ryan Myers, who serves as CEO, and Kristian DiMatteo, who serves as COO [UMass Lowell, 2025]; [ZoomInfo, 2026]. Myers's background includes time at Northeastern University, and DiMatteo previously worked with MassChallenge, the Boston-based accelerator [Crunchbase, 2025]. The company was a 2020 finalist in the M2D2 $200K Challenge run by UMass Lowell [M2D2, 2020], a regional medtech proving ground, and has continued to surface in New England medtech competitions since.
The honest counterfactual
Noninvasive ICP is a category that has attracted serious attempts before. The bear case is simple: the bar set by an intraparenchymal bolt is high, and the FDA will want to see that IPASS readings agree with invasive ICP across a clinically meaningful range, not just on average. Competitors in adjacent neuro-monitoring, including InfraScan, Brainspace, and Bioscan Research, have pursued various optical and ultrasound approaches with mixed clinical traction. What bulls would answer is that CranioSense is not selling IPASS as a replacement for the bolt in the neuro-ICU on day one. The company's framing is interim management, the window when a clinician needs to make a decision and an invasive monitor is not yet in place [MTEC, 2026]. That is a defensible regulatory and clinical wedge, and it is the kind of indication the FDA has historically been willing to clear on noninferiority-style evidence rather than head-to-head superiority.
What to watch
The next twelve months are about evidence. The grant award is explicitly tied to validation work, so the milestones to track are the readouts from CranioSense's clinical studies, any peer-reviewed publication of agreement data against invasive ICP, and the company's choice of regulatory pathway: a 510(k) leaning on a predicate, or a De Novo request if IPASS is positioned as a new device class. A priced equity round following a clean validation readout would be the natural next financing event, and it would tell the market what an investor base outside the federal grant system thinks the technology is worth.
For now, the patient population to keep in mind is the one that frames this whole bet: the TBI patient in a community ED, the suspected idiopathic intracranial hypertension patient cycling through repeat lumbar punctures, and the post-surgical neuro patient whose clinician would very much like to know what is happening inside the skull without making a new hole to find out.
Pulse Raman, Health and Bio Correspondent, Startuply.